BioAscent’s 125k diversity Compound Cloud collection is available both for use in your diversity- based high-throughput screening (HTS) projects and as customised sets for targeted screening projects at BioAscent, and for on-demand purchase for your internal use via the Compound Cloud website.
The library was originally part of MSD’s screening collection. It was selected by Organon/Schering-Plough/MSD medicinal chemists to be a diverse set and to provide good medicinal chemistry starting points for discovery programmes.
Compounds are stored in DMSO solution (2mM & 10mM) in individual-use REMP tubes, with 86,000 also held as solid stock at BioAscent. The collection is comprised of commercially available compounds from various suppliers, so solid stock is also available commercially (e.g. via our partner Molport).
Compounds were selected using drug-like properties, e.g:
With regard to physicochemical properties the compounds are, in general, lead-like with the following median properties:
As an illustration of the diversity, the set contains ca.57k different Murcko Scaffolds and ca. 26.5k Murcko Frameworks.
To demonstrate the utility of the library, we have screened a subset of 5,000 compounds designed to be structurally representative of the full library against 35 diverse biological targets. These included enzymes, nuclear hormone receptors, GPCRs, protein-protein interactions, protein-RNA interactions, viral interferon antagonists; as well as phenotypic cell growth / cell death assays. High quality hits resulted from a number of these screens. For further details, please see the Download section.
In addition to the full library, three smaller diversity subsets are available for use in screening at BioAscent:
Of course, using our computational expertise and Compound Management cherry picking capabilities, we can design and pick custom subsets for your target – or you computational experts can select their own. And we can combine compounds from our library with externally sourced compounds (see below).
As part of our assay development/validation process we have a set of known problematic compounds that can cause false positive results during screening (e.g. aggregators, redox cyclers, chelators etc.) which we use to identify potential liabilities. We then either optimise the assay to minimise these ‘false positive’ effects, or in cases where we still see them appearing we can put in place appropriate de-selection assays to identify them quickly. This link gives an outline of a project where we identified a Redox Cycling issue and how we addressed it to minimise the likelihood of progressing false positives.
Should you wish to select and aggregate a custom, targeted library for your drug target from a diversity of suppliers, we can work with compound aggregators (e.g. Molport) to source, aggregate, and securely store your library, and to cherry-pick from it and create assay ready plates.